← Back to headlines
Sumitomo Pharma Shares Slide Despite Panel Backing for Parkinson's Treatment
Sumitomo Pharma's shares fell nearly 16% despite a panel's recommendation for its iPS-derived Parkinson's treatment.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
